Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis:A scoping review
作者机构：School of Pharmaceutical SciencesSiksha‘O’Anusandhan(Deemed to be University)BhubaneswarIndia School of Pharmacy and Life SciencesCenturion University of Technology and ManagementOdishaIndia
出 版 物：《Asian Pacific Journal of Tropical Medicine》 (亚太热带医药杂志（英文版）)
年 卷 期：2022年第15卷第7期
页 面：293-307页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Visceral leishmaniasis Doxorubicin Passive targeting Repositioning Non-PEGylated liposome encapsulated doxorubicin Resistance
摘 要：Visceral leishmaniasis(VL),also known as Kala-azar,is caused by Leishmania(L.)donovani complex,which includes *** and *** and is associated with a high death rate as compared to the cutaneous and subcutaneous *** of VL includes chemotherapeutic agents which are associated with some major hurdles like toxicities,parenteral administration,high cost,parasite resistance and ***,there is an urgent requirement to develop novel chemotherapeutic agents or repurposing of existing drugs against *** formulation of new chemical entity for the treatment of VL is laborious,time consuming and associated with huge financial ***,screening of existing chemotherapeutic agents is a good alternative to avail cost-effective treatment option for ***-PEGylated liposome encapsulated doxorubicin(Myocet®)is proposed as an alternative treatment option for VL in this review ***,we covered the fundamental aspects of VL,loophole associated with available current treatment strategies and non-PEGylated liposome encapsulated doxorubicin as a novel alternative formulation for treating VL,as this liposomal delivery system of doxorubicin might passively target the intra-cellular regions of macrophage.
维普期刊数据库